Fibrocor

Fibrocor is a company headquartered in Canada. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Fibrocor develops first-in-class therapeutics targeting fibroblast activation to treat genetically-driven fibrotic kidney diseases such as Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease (ADPKD). Their approach is based on biomarker-driven discovery using extensive human fibrosis tissue biobanks.